FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de stacks

Pathogen Shield Protocol

Immune Supportadvanced
19
Share
Pépétides

4

Moyenne journalière en mcg

1,593

Niveau

advanced

Ajouté

May 16, 2026

Aperçu

The Pathogen Shield Protocol is an advanced immunomodulatory stack designed to fortify the body's innate and adaptive immune defenses against bacterial, viral, and fungal threats. This protocol combines four synergistic peptides that work across multiple immune pathways to create a comprehensive shield against pathogens. Thymosin Alpha-1, administered at 1500mcg three times per week, serves as the cornerstone of this stack by enhancing T-cell maturation and function. Originally derived from thymic tissue, this peptide has been extensively studied in clinical settings for hepatitis B and C treatment, demonstrating significant improvements in immune cell activation and pathogen clearance. It primes dendritic cells and upregulates MHC class I expression, improving the immune system's ability to recognize and eliminate infected cells. LL-37, dosed at 200mcg daily, is a human cathelicidin antimicrobial peptide that provides direct pathogen-killing activity. It disrupts microbial membranes on contact while simultaneously recruiting immune cells to sites of infection. Research has shown LL-37 exhibits broad-spectrum activity against gram-positive and gram-negative bacteria, enveloped viruses, and fungi. KPV at 500mcg daily adds potent anti-inflammatory signaling that prevents immune overactivation while maintaining pathogen vigilance. This tripeptide fragment of alpha-MSH modulates NF-kB pathways, reducing excessive cytokine production without suppressing necessary immune responses. BPC-157 at 250mcg daily supports mucosal barrier integrity throughout the gastrointestinal tract, which represents the body's largest immune interface. By strengthening gut lining and promoting angiogenesis, it helps maintain the first line of defense against ingested pathogens. This stack is suited for individuals with recurrent infections, those in high-exposure environments, or anyone recovering from immune-compromising treatments. The protocol is best administered in 8-12 week cycles with periodic bloodwork to monitor immune markers. Morning dosing of LL-37 and KPV is recommended, with Thymosin Alpha-1 on non-consecutive days.

Protocole de dose

Thymosin Alpha-1

3 times per week

Lire plus sur Thymosin Alpha-1 →

1,500 mcg

par dose

200 mcg

par dose

500 mcg

par dose

250 mcg

par dose

Objectifs & Preuves

Niveau d'évidence :community

Comments

Sign in to join the discussion

Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.